{"id":"W2610975296","doi":"10.5430/jst.v7n2p28","title":"A phase II trial of neoadjuvant doxorubicin plus cyclophosphamide followed by lapatinib plus docetaxel sequential with adjuvant trastuzumab for treatment of early HER2 positive breast cancers","year":2017,"lang":"en","type":"article","venue":"Journal of Solid Tumors","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Lapatinib; Docetaxel; Breast cancer; Internal medicine; Oncology; Pertuzumab; Population; Anemia; Cyclophosphamide; Lumpectomy; Phases of clinical research; Gastroenterology; Surgery; Chemotherapy; Cancer; Mastectomy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006709985,0.0004328119,0.002161152,0.0002674361,0.0003013618,0.00004589637,0.0004607942,0.0001387793,0.00007926992],"category_scores_gemma":[0.0001754464,0.000304034,0.0006434859,0.00016642,0.0005319847,0.0002872109,0.00006192701,0.0003186658,0.00000133801],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0023012,"about_ca_system_score_gemma":0.005087795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004131002,"about_ca_topic_score_gemma":0.0002577926,"domain_scores_codex":[0.995974,0.0001069332,0.001511679,0.000377389,0.001345276,0.0006847403],"domain_scores_gemma":[0.9952053,0.0001580956,0.002476431,0.0006132328,0.0009960856,0.0005508413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8386388,0.007693755,0.001419754,0.0005139657,0.00337682,0.002478947,0.009841199,0.0005426728,0.09130199,0.00002994823,0.004003377,0.04015872],"study_design_scores_gemma":[0.5539663,0.2053298,0.003243675,0.002879434,0.001571486,0.001605899,0.001298482,0.0006623402,0.2281022,0.00004017449,0.0008253314,0.0004748757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932582,0.0007846582,0.0003168534,0.0009134398,0.0005547899,0.002324397,0.001503675,0.00001110704,0.0003329123],"genre_scores_gemma":[0.9973485,0.0003374266,0.000766642,0.00003803731,0.000694857,0.00009996269,0.00002783101,0.00008306348,0.00060371],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2846726,"threshold_uncertainty_score":0.9999412,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03530434100853432,"score_gpt":0.3800850140741496,"score_spread":0.3447806730656153,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}